KR100678568B1 - Composition Comprising Bamboo Extract for Treating or Preventing Diabetes - Google Patents
Composition Comprising Bamboo Extract for Treating or Preventing Diabetes Download PDFInfo
- Publication number
- KR100678568B1 KR100678568B1 KR1020050050175A KR20050050175A KR100678568B1 KR 100678568 B1 KR100678568 B1 KR 100678568B1 KR 1020050050175 A KR1020050050175 A KR 1020050050175A KR 20050050175 A KR20050050175 A KR 20050050175A KR 100678568 B1 KR100678568 B1 KR 100678568B1
- Authority
- KR
- South Korea
- Prior art keywords
- bamboo
- composition
- reference example
- bamboo extract
- extract
- Prior art date
Links
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims abstract description 105
- 235000017491 Bambusa tulda Nutrition 0.000 title claims abstract description 105
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims abstract description 105
- 241001330002 Bambuseae Species 0.000 title claims abstract description 104
- 239000011425 bamboo Substances 0.000 title claims abstract description 104
- 239000000284 extract Substances 0.000 title claims abstract description 93
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 95
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 238000000605 extraction Methods 0.000 description 15
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000002904 solvent Substances 0.000 description 11
- 208000002249 Diabetes Complications Diseases 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 5
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 240000008120 Dendrocalamus strictus Species 0.000 description 2
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000035859 Drug effect increased Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- -1 sulfonylureas Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZSJLQEPLLKMAKR-YDEIVXIUSA-N 1-methyl-1-nitroso-3-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea Chemical compound O=NN(C)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-YDEIVXIUSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000209134 Arundinaria Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000209128 Bambusa Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000745988 Phyllostachys Species 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000216609 Pseudosasa Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 대나무 추출물을 포함하는 당뇨병 치료 또는 예방용 조성물을 개시한다.The present invention discloses a composition for treating or preventing diabetes comprising bamboo extract.
대나무 추출물, 당뇨병 Bamboo Extract, Diabetes
Description
본 발명은 대나무 추출물을 포함하는 당뇨병 치료 또는 예방용 조성물에 관한 것이다.The present invention relates to a composition for treating or preventing diabetes comprising a bamboo extract.
당뇨병이란 췌장의 베타 세포에서 분비되는 글루코스 조절 호르몬인 인슐린이 부족하거나 제대로 작용하지 못하여 혈액 속의 혈당이 에너지로 이용되지 않고 혈액 속에 쌓여 고혈당을 유발하고 요중에 당이 검출되는 증상을 말한다. Diabetes is a condition in which insulin, a glucose-regulating hormone secreted from the beta cells of the pancreas, is insufficient or does not function properly, causing blood glucose to accumulate in the blood instead of being used as energy, causing high blood sugar and detecting glucose in the urine.
당뇨병은 보통 인슐린 의존형 당뇨병(I형 당뇨병)과 인슐린 비의존형 당뇨병(II형 당뇨병)으로 구분된다. 인슐린 의존형 당뇨병은 바이러스 감염 등이 원인이 되어 췌장의 베타세포가 파괴된 결과 인슐린이 분비되지 않아 발병하며, 주로 10 내지 20대의 젊은 연령층에서 발병되기 때문에 소아 당뇨병이라고도 하는데, 인슐린이 외부에서 공급되지 않으면 생명유지가 어렵기 때문에 붙여진 이름이다. 인슐린 비의존형 당뇨병은 췌장의 베타 세포에서 인슐린이 분비되기는 하지만 그 양이 부족하고 그 작용력이 감소하여 발병하며, 주로 30대 이후에 발병하므로 성인형 당뇨병이라고도 한다. 생명유지를 위해서는 외부로부터 인슐린을 반드시 공급할 필요 가 없다고 하여 인슐린 비의존형 당뇨병이라 불리고 있지만, 그렇다고 고혈당 치료를 위하여 인슐린 치료가 필요하지 않다는 의미는 아니다. Diabetes is usually divided into insulin dependent diabetes (type I diabetes) and insulin independent diabetes (type II diabetes). Insulin-dependent diabetes mellitus is caused by viral infections and is caused by the destruction of the beta cells of the pancreas, resulting in insulin secretion. It is also known as pediatric diabetes because it occurs mainly in young age groups of 10 to 20 years. The name is given because it is difficult to maintain life. Insulin-independent diabetes is caused by the lack of insulin in the pancreatic beta cells, but the amount is reduced and its action is caused, mainly after 30s, it is also called adult diabetes. Although it is called insulin-independent diabetes, it does not mean that insulin therapy is not necessary to treat hyperglycemia because it does not necessarily need to supply insulin from the outside to maintain life.
당뇨가 오래 지속되면 포도당이 제대로 체내에 흡수되지 못하여 영양 공급의 불균형으로 인해 각종 대사장애가 발생함에 따라 여러 당뇨 합병증이 발병하게 된다.If diabetes persists for a long time, glucose is not properly absorbed into the body, and various metabolic disorders occur due to various metabolic disorders due to an imbalance in nutritional supply.
당뇨 합병증으로서는 신경섬유와 신경 막이 손상되어 발생하는 신경 합병증, 당뇨성 망막증(비증식성 망막증, 증식성 망막증, 당뇨성 백내장), 신부전증, 성기능 장애, 피부질환(알레르기), 고혈압, 동맥 경화증, 뇌졸증(중풍), 심장병(심근경색증, 협심증, 심장마비), 괴저 등을 들 수 있다.Diabetes complications include nerve complications caused by damage to nerve fibers and nerve membranes, diabetic retinopathy (non-proliferative retinopathy, proliferative retinopathy, diabetic cataracts), renal failure, sexual dysfunction, skin diseases (allergic), hypertension, atherosclerosis, stroke ( Stroke, heart disease (myocardial infarction, angina pectoris, heart attack), and gangrene.
당뇨병 치료에는 비구아니드(biguanides), 티아졸리딘디온 (thiazolidinediones), 설포닐우레아(sulfonylureas), 벤조산(benzoic acid) 유도체 및 α-글루코시다제 저해제(α-glucosidase inhibitor) 등이 사용되고 있으나, 이들 약물을 이용한 당뇨병 치료는 많은 부작용이 따르고 있어, 세계보건기구(WHO)는 당뇨병에 부작용이 적은 천연물의 이용을 적극 추천하고 있다(Grover J.K., Vats. V., Rathi. S.S., Journal of Ethnopharmacology, 73, pp461-470, 2000).Biguanides, thiazolidinediones, sulfonylureas, benzoic acid derivatives and α-glucosidase inhibitors are used to treat diabetes. Diabetes treatment with drugs has many side effects, and the World Health Organization (WHO) strongly recommends the use of natural products with fewer side effects. (Grover JK, Vats. V., Rathi. SS, Journal of Ethnopharmacology, 73 , pp 461-470, 2000).
당뇨병 치료에 효과가 있다고 보고된 천연물로서는 뜸부기 추출물(대한민국 특허 제464815호), 잔나비걸상버섯으로부터 분리한 아플아나산 유도체 화합물(대한민국 특허 제457690호), 헛개나무의 추출물(대한민국 특허 제417287호), 참당귀에서 분리한 다당류(국제공개 제2001-60386호), 반추동물의 담즙(미국특허 제6451355호) 등을 예시할 수 있다.Natural products reported to be effective in treating diabetes include moxibustion extracts (Korean Patent No. 464815), Apanaic acid derivative compounds isolated from Jangung Beetle Mushrooms (Korean Patent No. 457690), and extracts of hawthorn trees (Korean Patent No. 441787). , Polysaccharides isolated from Korean Angelica gigas (International Publication No. 2001-60386), bile of ruminant animals (US Patent No. 6645355) and the like.
본 발명도 천연물인 대나무 추출물의 당뇨병 치료 또는 예방 효과를 개시한다.The present invention also discloses a diabetic treatment or prevention effect of the natural bamboo extract.
본 발명의 목적은 대나무 추출물을 포함하는 당뇨병 치료 또는 예방용 조성물을 제공하는데 있다.An object of the present invention to provide a composition for treating or preventing diabetes comprising bamboo extract.
본 발명의 기타의 목적이나 구체적인 양태는 이하에 제시할 것이다.Other objects and specific aspects of the present invention will be presented below.
일 측면에 있어서, 본 발명은 당뇨병 치료 또는 예방용 조성물을 제공한다.In one aspect, the present invention provides a composition for treating or preventing diabetes.
본 발명자들은 췌장의 인슐린 생성 베타 세포를 파괴하는 세포독성물질인 스트렙토조토신(streptozotocin)을 실험동물에 투여하여 고혈당을 유발한 다음, 그 실험동물에 대나무 줄기를 절단하여 진액 형태로 얻은 대나무 추출물과 대나무 줄기를 톱밥 형태로 분쇄하고 그 분쇄물에 추출 용매로서 물 또는 에탄올을 가하여 얻은 대나무 추출물을 투여한 경우, 실험동물의 혈당이 저하됨을 확인할 수 있었다.The present inventors induce high blood sugar by administering streptozotocin, a cytotoxic substance that destroys insulin-producing beta cells of the pancreas, to a laboratory animal, and then cut bamboo stems to the laboratory animal, When the bamboo stem was crushed in the form of sawdust and the bamboo extract obtained by adding water or ethanol as the extraction solvent to the pulverized product, it was confirmed that the blood sugar of the experimental animal is lowered.
따라서 본 발명의 당뇨병 치료 또는 예방용 조성물은 대나무 추출물을 포함함을 특징으로 한다. Therefore, the composition for treating or preventing diabetes of the present invention is characterized in that it comprises a bamboo extract.
청구범위를 포함하는 본 명세서에서, 상기 "대나무 추출물"이란 그것이 당뇨병 치료 또는 예방 효과, 구체적으로 혈당 강하 효과를 가지는 한 그것이 얻어지는 대나무의 종류를 불문하고 또 그것의 추출 방법을 불문하고, 분류학상 대나무로 분류되는 식물의 줄기로부터 얻어진 고형상(solid phase) 또는 액상(liquid phase)의 추출물로서 정의된다.In the present specification, including the claims, the term "bamboo extract" means taxa regardless of the type of bamboo from which it is obtained, as well as its extraction method, as long as it has a diabetic therapeutic or prophylactic effect, specifically a hypoglycemic effect. It is defined as an extract of a solid phase or liquid phase obtained from the stem of a plant classified into.
대나무의 종류를 불문하므로, 상기 대나무 추출물은 왕대속(Phyllostachys)에 속하는 대나무로부터 얻어진 추출물과, 해장죽속(Arundinaria)에 속하는 대나무로부터 얻어진 추출물과, 조릿대속(Sasa)에 속하는 대나무로부터 얻어진 추출물과, 및 이대속(Pseudosasa)에 속하는 대나무로부터 얻어진 추출물을 모두 포함하는 개념으로서 이해되며, 또 추출 방법을 불문하므로, (i) 세절된 대나무에 직·간접적으로 열을 가하여 얻어진 추출물과, (ii) 살아있는 대나무의 윗부분을 절단하고 그 절단된 부위에서 얻어지는 진액 형태의 추출물과, (iii) 세절된 또는 분쇄된 대나무를 추출 용매 예컨대, 물, 증류수, 알콜(바람직하게는 탄소수가 5 이하의 저급 알콜), 핵산, 에틸 아세테이트, 아세톤, 클로로포름, 메틸렌 클로라이드 또는 이들의 혼합 용매로 추출하여 얻어진 추출물을 모두 포함하는 개념으로서 이해된다. Regardless of the type of bamboo, the bamboo extract is an extract obtained from bamboo belonging to Phyllostachys, an extract obtained from bamboo belonging to Arundinaria, an extract obtained from bamboo belonging to Sasa, And extracts obtained from bamboos belonging to Pseudosasa, and regardless of the extraction method, (i) extracts obtained by applying heat directly or indirectly to the shredded bamboo, and (ii) living Extracts in the form of a sperm obtained by cutting off the upper part of the bamboo and from the cut site; Extract obtained by extraction with nucleic acid, ethyl acetate, acetone, chloroform, methylene chloride or a mixed solvent thereof It is understood as a concept that includes all.
본 발명의 하기 실시예에서 사용된 대나무 추출물(참고예의 대나무 추출물)은 상기 (ii)의 방식으로 얻어진 대나무 추출물과 상기 (iii)의 방식으로 얻어진 대나무 추출물 중 특히 추출 용매로서 물 또는 에탄올을 사용하여 얻어진 것인데, 이러한 대나무 추출물 모두가 하기 실시예에서 보여지듯이 그 효과에 있어서는 차이가 있을 지라도 스트렙토조토신에 의하여 유발된 실험동물의 고혈당을 낮추는 결과를 보여주었다. The bamboo extract used in the following examples of the present invention (bamboo extract of the reference example) is a bamboo extract obtained by the method of (ii) and bamboo extract obtained by the method of (iii), in particular, using water or ethanol as an extraction solvent. All of these bamboo extracts were shown to lower the hyperglycemia of the experimental animals induced by streptozotocin, although differences in their effects, as shown in the following examples.
이러한 결과는 본 발명의 하기 실시예에서 사용된 대나무 추출물이 서로 다른 여러 추출 방법에 의하여 얻어진 것이라는 점에서 추출 방식을 달리한 여타의 다른 대나무 추출물도 유사한 결과를 보여줄 것임을 예측하게 해주는 것이라 할 수 있다. These results can be said to predict that the other bamboo extract different from the extraction method will show similar results in that the bamboo extract used in the following examples of the present invention is obtained by different extraction methods.
따라서 당업자라면 본 발명의 하기 실시예에 기초하는 한 그의 통상의 능력 범위내에서 하기 참고예의 대나무 추출물 이외의 다른 대나무 추출물도 당뇨병 치료 또는 예방 효과 즉 혈당 강하 효과를 가질 개연성이 있다고 기대할 것이며, 또한 그의 통상의 능력 범위내에서 혈당 강하 효과가 있는 대나무 추출물을 선별·확인할 수 있을 것이다.Therefore, those skilled in the art will expect that bamboo extracts other than the bamboo extracts of the following reference examples also have a probable effect of treating or preventing diabetes, that is, hypoglycemic effect, within the range of their usual ability, based on the following examples of the present invention. Bamboo extracts with a hypoglycemic effect can be screened and identified within the usual capacity.
그러므로 본 발명의 실시예가 참고예의 대나무 추출물을 가지고 혈당 강하 효과를 확인하였다고 하더라도 상기 "대나무 추출물"에는 하기 참고예의 대나무 추출물 이외에도 혈당 강하 효과가 있는 모든 대나무 추출물이 포함되는 것으로 이해되어야 한다.Therefore, even if the embodiment of the present invention confirmed the hypoglycemic effect with the bamboo extract of the reference example, the "bamboo extract" should be understood to include all the bamboo extract having a hypoglycemic effect in addition to the bamboo extract of the following reference example.
그럼에도 바람직하게는 상기 "대나무 추출물"은 하기 참고예의 대나무 추출물로서 이해되어지며, 더 바람직하게는 상기 열거된 추출 용매 중 물 또는 에탄올을 사용하여 얻어진 대나무 추출물로서 이해되어진다. 더욱 바람직하게는 추출 용매 중 70%(본 명세서에서 %는 부피 백분율(v/v)을 의미한다. 이하 같다) 이상의 에탄올을 사용하여 얻어진 대나무 추출물로서 이해된다. 가장 바람직하게는 80% 이상의 에탄올을 사용하여 얻어진 대나무 추출물로서 이해된다. 그것은 하기 실시예에서 보여지는 바와 같이 추출 용매로서 70% 에탄올과 80% 에탄올로 얻어진 대나무 추출물을 사용하였을 때가 40% 에탄올, 50% 에탄올 도는 60% 에탄올로 얻어진 대나무 추출물을 사용하였을 때의 혈당 강화 효과와는 질적으로 다른 급격한 혈압 강하 효과가 있었기 때문이다. Nevertheless preferably the "bamboo extract" is understood as the bamboo extract of the following reference example, and more preferably as the bamboo extract obtained using water or ethanol in the extraction solvents listed above. More preferably, it is understood as a bamboo extract obtained using ethanol of at least 70% of the extraction solvent (% herein means volume percentage (v / v). Most preferably as a bamboo extract obtained using at least 80% ethanol. As shown in the following examples, the effect of enhancing blood sugar when using bamboo extracts obtained with 70% ethanol and 80% ethanol as the extraction solvent was 40% ethanol, 50% ethanol or 60% ethanol. This is because there was a sudden drop in blood pressure.
상기에서 그리고 청구범위를 포함하는 이하에서, "70% 이상의 에탄올" 또는 "80% 이상의 에탄올"이란 에탄올을 70% 이상 또는 80% 이상의 농도로 포함하는 모든 혼합 용매를 의미하는 것으로서 이해될 수 있다. 에탄올을 70% 이상의 농도로 포함한다면 상기 혼합 용매는 2종 이상의 용매의 임의의 혼합물일 수 있다. 예컨대, 물, 아세톤 그리고 에탄올의 혼합 용매의 경우도 에탄올이 70% 이상의 농도로 포함되어 있기만 한다면 상기 70% 이상의 에탄올에 해당한다. Above and below, including the claims, "70% or more ethanol" or "80% or more ethanol" can be understood as meaning any mixed solvent comprising ethanol in a concentration of 70% or more or 80% or more. The mixed solvent may be any mixture of two or more solvents if it comprises ethanol at a concentration of at least 70%. For example, a mixed solvent of water, acetone and ethanol also corresponds to 70% or more of ethanol as long as ethanol is contained in a concentration of 70% or more.
한편, 청구범위를 포함하는 본 명세서에서 "당뇨병"이란 전술한 바의 인슐린 의존형 당뇨병과 인슐린 비의존형 당뇨병을 포함하는 의미이며, 나아가 다른 질병 등으로 인하여 췌장이 손상됨에 따라 발생하는 당뇨병 예컨대, 갑상선 기능 항진증, 부신피질 기능 항진증, 성장호르몬 과다증 또는 카테콜라민 과다증에 의한 당뇨병, 임신성 당뇨병을 포함하는 의미이다.On the other hand, in the present specification, including the claims, "diabetes" is meant to include insulin-dependent diabetes and insulin-independent diabetes as described above, furthermore diabetes, such as thyroid function that occurs when the pancreas is damaged due to other diseases, etc. Diabetes mellitus, gestational diabetes mellitus due to hyperlipidemia, adrenal cortical hyperactivity, growth hormone hyperplasia or catecholamine hyperplasia.
본 발명의 당뇨병 치료 또는 예방용 조성물에, 그 유효 성분인 대나무 추출물은 그것이 당뇨병 치료 또는 예방 효과 또는 혈당 강하 효과를 나타낼 수 있는 한 임의의 양으로 포함될 수 있는데, 바람직하게는 본 발명의 조성물 전체 중량을 기준으로 하였을 때 0.001% 이상에서 99.999% 이하로 포함될 수 있다.In the composition for treating or preventing diabetes of the present invention, the bamboo extract as an active ingredient thereof may be included in any amount as long as it can exhibit the effect of treating or preventing diabetes or lowering blood sugar, preferably the total weight of the composition of the present invention. On the basis of the base may be included in more than 0.001% 99.999%.
다른 측면에 있어서, 본 발명은 대나무 추출물을 포함하는 당뇨 합병증 치료 또는 예방용 조성물을 제공한다.In another aspect, the present invention provides a composition for treating or preventing diabetes complications comprising the bamboo extract.
당뇨 합병증의 치료 또는 예방을 위해서는 고혈당을 정상 수준으로 낮추는 것이 일반적으로 필요하다는 점을 고려할 때(김정상, 나창수 : 배에서 추출한 Phenollic Compound가 Streptozotocin으로 유발된 고혈당 생쥐에 미치는 영향, 한 국식품영양과학회지, 31(6), 1107-1111, 2002), 혈당 강하 효과를 나타내는 대나무 추출물을 유효 성분으로 포함하는 본 발명의 당뇨 합병증 치료 또는 예방용 조성물은 당뇨 합병증의 치료 또는 예방 목적으로 단독으로 또는 다른 당뇨 합병증 치료제나 예방제와 병용하여 사용될 수 있다.Considering that it is generally necessary to reduce hyperglycemia to normal levels for the treatment or prevention of diabetic complications (Kim, Sang-Soo, Na Chang-Soo: Effect of Phenollic Compounds Extracted from Pear on Streptozotocin-induced Hyperglycemic Mice, Korean Journal of Food and Nutrition Science) , 31 (6), 1107-1111, 2002), the composition for treating or preventing diabetes complications of the present invention comprising as an active ingredient a bamboo extract exhibiting a hypoglycemic effect is used alone or for other diabetics for the treatment or prevention of diabetes complications. It can be used in combination with a therapeutic or prophylactic agent.
청구범위를 포함하는 본 명세서에서, 상기 "당뇨 합병증"은 당뇨병이 원인이 되어 이차적으로 발병하는 모든 질환을 포함하는 의미인데, 그러한 질환으로서 예컨대 앞서 열거한 바의 신경 합병증, 당뇨성 망막증, 신부전증, 성기능 장애, 피부질환, 고혈압, 동맥 경화증, 뇌졸증, 심장병, 괴저 등을 들 수 있다.In the present specification, including the claims, the "diabetic complication" is meant to include all diseases secondary to the onset of diabetes, such as neurological complications, diabetic retinopathy, renal failure, Sexual dysfunction, skin diseases, high blood pressure, atherosclerosis, stroke, heart disease, gangrene and the like.
한편, 상기 본 발명의 당뇨 합병증 치료 또는 예방용 조성물에 있어서, 대나무 추출물의 의미는 그 바람직한 양태를 포함하여 전술한 바가 그대로 유효하다.On the other hand, in the composition for treating or preventing diabetic complications of the present invention, the meaning of the bamboo extract, including the preferred embodiment thereof is effective as it is.
본 발명의 당뇨병 치료 또는 예방용 조성물과 당뇨 합병증 치료 또는 예방용 조성물은 구체적인 양태에 있어서 약제학적 조성물로 파악될 수 있다.The composition for treating or preventing diabetes and the composition for treating or preventing diabetes complications of the present invention may be regarded as a pharmaceutical composition in a specific embodiment.
본 발명의 약제학적 조성물은 유효 성분으로서 상기 대나무 추출물 이외에 약제학적으로 허용되는 담체를 포함할 수 있는데, 이러한 약제학적으로 허용되는 담체는 약품 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘, 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 또한 첨가제로서 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존 제 등을 추가로 포함할 수 있다.The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier in addition to the bamboo extract as an active ingredient, such a pharmaceutically acceptable carrier is commonly used in pharmaceutical preparations, lactose, dextrose, water Cross, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydride Oxybenzoate, talc, magnesium stearate, mineral oil, and the like. The pharmaceutical compositions of the present invention may also further comprise lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives and the like as additives.
상기 담체는 본 발명의 약제학적 조성물에 그것의 전체 중량에 대하여 약 1 중량 % 내지 약 99.999 중량 %, 바람직하게는 약 50 중량% 내지 약 99.999 중량 %로 포함될 수 있으며, 상기 첨가제는 약 0.1 중량 % 내지 약 20 중량 %로 포함될 수 있다. The carrier may be included in the pharmaceutical composition of the present invention in an amount of about 1% by weight to about 99.999% by weight, preferably about 50% by weight to about 99.999% by weight, with the additive being about 0.1% by weight. To about 20% by weight.
한편, 본 발명의 약제학적 조성물은 다양한 경로로 투여될 수 있는데, 예컨대 경구 또는 직장에의 직접 투여되거나, 정맥, 근육, 피하, 자궁내 경막 등에의 주사 투여 될 수 있다.On the other hand, the pharmaceutical composition of the present invention can be administered by various routes, for example, orally or rectally, or by injection into veins, muscles, subcutaneous, intrauterine dural, and the like.
본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기내에 내입시켜 제조될 수 있다. 이때 제형은 용액, 현탁액 또는 유화액 형태이거나 엘렉시르제, 엑스제, 분말제, 과립제, 정제, 경고, 도고제, 로션, 연고 등을 포함할 수 있다.The pharmaceutical compositions of the present invention may be prepared in unit dose form or formulated using pharmaceutically acceptable carriers and / or excipients or incorporated into multi-dose containers. In this case, the formulation may be in the form of a solution, a suspension or an emulsion, or may include an exercire, an excipient, a powder, a granule, a tablet, a warning, a coughing agent, a lotion, an ointment, and the like.
본 발명의 약제학적 조성물은 그 1일 투여량이 통상 0.001 ~ 150 mg/kg 체중 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 본 발명의 약제학적 조성물의 투여량은 투여 경로, 환자의 연령, 성별, 체중, 환자의 중증도 등의 여러 관련 인자에 비추어 결정되어지는 것이므로 상기 투여량은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 아니된다. The daily dosage of the pharmaceutical composition of the present invention is usually 0.001 ~ 150 mg / kg body weight range, it can be administered once or divided into several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as the route of administration, the age, sex, weight of the patient, and the severity of the patient, the dosage limits the scope of the present invention in any aspect. It should not be understood as.
본 발명의 당뇨병 치료 또는 예방용 조성물과 당뇨 합병증 치료 또는 예방용 조성물은 구체적인 양태에 있어서 식품 조성물로 파악될 수 있다.The composition for treating or preventing diabetes and the composition for treating or preventing diabetes complications of the present invention may be regarded as a food composition in a specific embodiment.
본 발명의 식품 조성물은 껌류, 비타민 복합제, 건강 보조식품, 특수 영양 보충용 식품, 기능성 음료 등으로 제조될 수 있다.The food composition of the present invention may be prepared from gums, vitamin complexes, dietary supplements, special nutritional supplements, functional drinks, and the like.
본 발명의 식품 조성물에는 대나무 추출물이 포함되는 이외에, 포도당, 과당과 같은 단당류, 말토스, 슈크로스와 같은 이당류, 또는 덱스트린, 사이클로덱스트린과 같은 다당류가 첨가될 수 있고, 자일리톨, 소르비톨, 에리트리톨 등의 당 알콜이 또한 첨가될 수 있고, 타우린, 스테비아 추출물과 같은 감미제 등이 또한 첨가될 수 있으며, 나아가 여타의 식품 첨가물이 첨가될 수 있다. In addition to the bamboo extract is included in the food composition of the present invention, glucose, monosaccharides such as fructose, disaccharides such as maltose, sucrose, or polysaccharides such as dextrin, cyclodextrin, and the like, and xylitol, sorbitol, erythritol, etc. Sugar alcohols may also be added, sweeteners such as taurine, stevia extract, and the like may also be added, and other food additives may also be added.
이하 본 발명을 실시예 및 실험예를 참조하여 설명한다. 그러나 본 발명의 범위가 이러한 실시예 및 실험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.
<참고예> <Reference Example> 대나무 추출액의 제조Preparation of Bamboo Extract
<참고예 1> 대나무 추출물의 제조예 1 Reference Example 1 Preparation Example 1 of Bamboo Extract
전라남도 담양군에 서식하는 3년생의 맹종죽의 줄기를 2004년 5월에 채취하고, 물로 깨긋이 수세한 후에 건조시켜 시료로서 사용하였다. 먼저 건조된 시료를 분쇄하여 대나무 톱밥을 준비한 다음, 2000ml 용량의 둥근 플라스크에 이 대나무 톱밥을 넣고 여기서 대나무 톱밥의 5 내지 10 배(대나무 톱밥의 중량 기준) 가량의 물을 첨가하여 95℃에서 3시간 정도 추출하였다. 추출액은 다시 감압농축기(Buchi Co. R-114, Germany)로 농축한 후 동결건조시켜 고형상의 대나무 추출물을 제조하였다.The stems of three-year-old bamboo shoots, which live in Damyang-gun, Jeollanam-do, were collected in May 2004, washed with water, dried and used as samples. First, prepare the bamboo sawdust by pulverizing the dried sample, and then put the bamboo sawdust into a 2000ml round flask and add about 5-10 times the bamboo sawdust (based on the weight of bamboo sawdust) for 3 hours at 95 ℃. To the extent extracted. The extract was concentrated again with a vacuum concentrator (Buchi Co. R-114, Germany) and then lyophilized to prepare a solid bamboo extract.
<참고예 2> 대나무 추출물의 제조예 2 Reference Example 2 Preparation Example 2 of Bamboo Extract
상기 <참고예 1>과 동일한 방법으로 대나무 추출물을 제조하되, 다만 시료를 2004년 5월에 채취한 맹종죽 줄기 대신에 2004년 10월 채취한 3년생의 솜대 줄기를 사용였다.Bamboo extracts were prepared in the same manner as in <Reference Example 1>, except that the three-year-old cotton rod stems collected in October 2004 were used instead of the stems of the bamboo shoots collected in May 2004.
<참고예 3> 대나무 추출물의 제조예 3 Reference Example 3 Preparation Example 3 of Bamboo Extract
전라남도 담양군에 서식하는 3년생의 맹종죽의 줄기를 2004년 5월에 채취하고, 수세·건조시킨 다음 이를 분쇄하여 대나무 톱밥을 준비하였다. 2000ml 용량의 둥근 플라스크에 대나무 톱밥을 넣고 여기서 대나무 톱밥의 10 배(대나무 톱밥의 중량 기준) 가량의 40%의 에탄올(물과 에탄올의 혼합 용매임; 이하 같음)을 첨가하여 40±2℃의 수욕상에서 3시간 동안 추출한 후 여지(Whatman NO.5A)로 여과하였다. 추출액은 다시 감압농축기(Buchi Co. R-114, Germany)로 농축한 후 동결건조시켜 고형상의 대나무 추출물을 제조하였다.The stems of three-year-old bamboo shoots, which live in Damyang-gun, Jeollanam-do, were collected in May 2004, washed, dried, and crushed to prepare bamboo sawdust. Put a bamboo sawdust into a 2000 ml round flask, and add 40% of ethanol (a mixed solvent of water and ethanol; same as below) about 10 times of bamboo sawdust (based on the weight of bamboo sawdust). The phases were extracted for 3 hours and then filtered over Whatman NO.5A. The extract was concentrated again with a vacuum concentrator (Buchi Co. R-114, Germany) and then lyophilized to prepare a solid bamboo extract.
<참고예 4> 대나무 추출물의 제조예 4 Reference Example 4 Preparation Example 4 of Bamboo Extract
상기 <참고예 3>과 동일한 방법으로 대나무 추출물을 제조하되, 다만 추출용매를 40% 에탄올 대신에 50%의 에탄올을 사용하였다. Bamboo extract was prepared in the same manner as in <Reference Example 3>, except that 50% of ethanol was used instead of 40% of ethanol.
<참고예 5> 대나무 추출물의 제조예 5 Reference Example 5 Preparation Example 5 of Bamboo Extract
상기 <참고예 3>과 동일한 방법으로 대나무 추출물을 제조하되, 다만 추출용매를 40% 에탄올 대신에 60%의 에탄올을 사용하였다. Bamboo extract was prepared in the same manner as in <Reference Example 3>, except that 60% ethanol was used instead of 40% ethanol as the extraction solvent.
<참고예 6> 대나무 추출물의 제조예 6 Reference Example 6 Preparation Example 6 of Bamboo Extract
상기 <참고예 3>과 동일한 방법으로 대나무 추출물을 제조하되, 다만 추출용매를 40% 에탄올 대신에 70%의 에탄올을 사용하였다. Bamboo extract was prepared in the same manner as in <Reference Example 3>, except that 70% ethanol was used instead of 40% ethanol as the extraction solvent.
<참고예 7> 대나무 추출물의 제조예 7 Reference Example 7 Preparation Example 7 of Bamboo Extract
상기 <참고예 3>과 동일한 방법으로 대나무 추출물을 제조하되, 다만 추출용매를 40% 에탄올 대신에 80%의 에탄올을 사용하였다. Bamboo extract was prepared in the same manner as in <Reference Example 3>, except that 80% of ethanol was used instead of 40% of ethanol.
<참고예 8> 대나무 추출물의 제조예 8 Reference Example 8 Preparation Example 8 of Bamboo Extract
상기 <참고예 3>과 동일한 방법으로 대나무 추출물을 제조하되, 다만 재료를 2004년 5월에 채취한 맹종죽 줄기 대신에 2004년 10월 채취한 3년생 솜대 줄기를 사용였다.Bamboo extract was prepared in the same manner as in <Reference Example 3>, except that the three-year-old cotton rod stem obtained in October 2004 was used instead of the stem of the bamboo shoots collected in May 2004.
<참고예 9> 대나무 추출물의 제조예 9 Reference Example 9 Preparation Example 9 of Bamboo Extract
상기 <참고예 4>와 동일한 방법으로 대나무 추출물을 제조하되, 다만 시료를 2004년 5월에 채취한 맹종죽 줄기 대신에 2004년 10월 채취한 3년생 솜대 줄기를 사용였다.Bamboo extracts were prepared in the same manner as in <Reference Example 4>, except that three-year-old cotton rod stems collected in October 2004 were used instead of the stems of the bamboo shoots collected in May 2004.
<참고예 10> 대나무 추출물의 제조예 10 Reference Example 10 Preparation Example 10 of Bamboo Extract
상기 <참고예 5>와 동일한 방법으로 대나무 추출물을 제조하되, 다만 시료를 2004년 5월에 채취한 맹종죽 줄기 대신에 2004년 10월 채취한 3년생 솜대 줄기를 사용였다.Bamboo extracts were prepared in the same manner as in <Reference Example 5>, except that the three-year-old cotton rod stems collected in October 2004 were used instead of the stems of the bamboo shoots collected in May 2004.
<참고예 11> 대나무 추출물의 제조예 11 Reference Example 11 Preparation Example 11 of Bamboo Extract
상기 <참고예 6>와 동일한 방법으로 대나무 추출물을 제조하되, 다만 시료를 2004년 5월에 채취한 맹종죽 줄기 대신에 2004년 10월 채취한 3년생 솜대 줄기를 사용였다.Bamboo extracts were prepared in the same manner as in <Reference Example 6>, except that three-year-old cotton rod stems collected in October 2004 were used instead of the stems of the bamboo shoots collected in May 2004.
<참고예 12> 대나무 추출물의 제조예 12 Reference Example 12 Preparation Example 12 of Bamboo Extract
상기 <참고예 7>와 동일한 방법으로 대나무 추출물을 제조하되, 다만 시료를 2004년 5월에 채취한 맹종죽 줄기 대신에 2004년 10월 채취한 3년생 솜대 줄기를 사용였다.Bamboo extracts were prepared in the same manner as in <Reference Example 7>, except that the three-year-old cotton rod stems collected in October 2004 were used instead of the stems of the bamboo shoots collected in May 2004.
<참고예 13> 대나무 추출물의 제조예 13 Reference Example 13 Preparation Example 13 of Bamboo Extract
2004년 5월에 3년생 맹종죽의 대나무 줄기를 절단하여 그 절단된 부위에서 추출되는 진액을 회수하고 이러한 진액 형태의 추출물을 동결 건조시켜 고형상의 추출물을 얻었다.In May 2004, bamboo stems of three-year-old bamboo shoots were cut to recover the essences extracted from the cut portions, and the extracts of the essence form were lyophilized to obtain solid extracts.
<참고예 14> 대나무 추출물의 제조예 14 Reference Example 14 Preparation Example 14 of Bamboo Extract
2004년 10월에 3년생 솜대의 대나무 줄기를 절단하여 그 절단된 부위에서 추출되는 진액을 회수하고 이러한 진액 형태의 추출물을 동결 건조시켜 고형상의 추출물을 얻었다.In October 2004, three-year-old bamboo stems were cut to recover the essences extracted from the cut portions, and the extracts in the form of the essences were lyophilized to obtain solid extracts.
<실시예> <Example> 대나무 추출물의 항당뇨 효과 평가Evaluation of Antidiabetic Effect of Bamboo Extract
<1> 실험 동물<1> experimental animals
실험동물은 다물사이언스(대한민국 대전)로부터 체중 약 250g 내외의 웅성 생쥐(ICR strain)를 구입하여 동신대학교(전남 광주 소재) 동물 사육실에서 고형사료(삼양사, 한국)와 물을 충분히 공급하면서 1주 이상 실험실 환경에 적응시킨 후 사용하였다. Experimental animals purchased male rats (ICR strain) weighing about 250g from Damul Science (Daejeon, Korea) and supplied solid feed (Samyangsa, Korea) and water at Dongshin University (Gwangju, Gwangju) for more than 1 week. Used after adapting to laboratory environment.
<2> 실험 동물의 고혈당 유발<2> hyperglycemia in experimental animals
고혈당 유발은 실험동물을 12시간 동안 절식시킨 다음 실험동물에 스트렙토 조토신(N-[methylnitrosocarbamoyl]-D-glucosamine 이하 "STZ",) 50㎎/㎏을 24 시간 간격으로 2회 복강 투여한 다음 3일 후에 STZ 100㎎/㎏을 1회 복강 투여하여 고혈당 생쥐를 유발하였다. 공복 시 정상 실험동물의 혈당이 70 ㎎/dL에서 고혈당 유발 후 약 113 ㎎/dL인 것을 실험에 사용하였다.Hyperglycemia induced by fasting the animals for 12 hours and then intraperitoneally administered 50 mg / kg of streptozotocin (N- [methylnitrosocarbamoyl] -D-glucosamine or less "STZ",) at 24 hour intervals 3 After 1 day, STZ 100 mg / kg was intraperitoneally administered to induce hyperglycemic mice. Fasting blood glucose of normal experimental animals at about 70 mg / dL was about 113 mg / dL after hyperglycemia was used in the experiment.
<3> 참고예의 대나무 추출물의 투여<3> Administration of Bamboo Extract of Reference Example
<참고예>의 대나무 추출물은 각각 상기 고혈당이 유발된 실험 동물에 2.0mg/kg을 6주 동안 매주 1회 경구 투여하였다. 한편 대조군으로서의 실험동물에는 대나무 추출물 대신에 생리 식염수를 투여하였다.Bamboo extract of <Reference Example> was orally administered once a week for 2.0 weeks / 2.0mg / kg to each of the hyperglycemic-induced experimental animals. On the other hand, the experimental animals as a control group was administered with saline instead of bamboo extract.
<4> 혈당 측정<4> blood sugar measurement
혈당 측정은 매주 1회 6주 동안 실시하였으며, 측정 12 시간 전에 금식을 시킨 다음 꼬리정맥에서 혈액을 채취하여 글루코미터 4(Glucometer 4)(Bayer Co., USA)로 측정하였다.Blood glucose was measured once a week for 6 weeks, fasted 12 hours before measurement, and blood was collected from the tail vein and measured by Glucometer 4 (Bayer Co., USA).
<5> 결과<5> results
결과는 하기 <표 1>과 같다.The results are shown in Table 1 below.
* 상기 <표 1>에서 각 수치는 측정된 혈당치(mg/dL)이다.* In Table 1, each value is a measured blood glucose level (mg / dL).
상기 <표 1>에서 보여지는 바와 같이, 참고예의 대나무 추출물 모두 항당뇨 효능을 나타내고 있다. 항당뇨 효능은 직접 채취 방식에 의하여 얻어진 대나무 추출물보다는 추출 용매를 사용하여 얻어진 대나무 추출물의 경우가 더 높고, 특히 추출 용매를 70% 또는 80% 에탄올을 사용한 경우가 가장 높았다. 특이한 것은 추출 용매로서 에탄올을 사용할 때 에탄올의 농도를 높일 수록 항당뇨 효능이 점차 증가하였다는 것과 70% 및 80% 에탄올의 경우에는 급격히 그 효과가 증가하였다는 것이다.As shown in Table 1, all of the bamboo extracts of the reference example show anti-diabetic efficacy. The anti-diabetic effect was higher for bamboo extracts obtained by using an extraction solvent than bamboo extracts obtained by the direct sampling method, and especially when 70% or 80% ethanol was used as the extraction solvent. Of particular note, when using ethanol as the extraction solvent, the antidiabetic effect increased gradually as the concentration of ethanol increased, and the effect increased rapidly in the case of 70% and 80% ethanol.
<제제예> <Example 약학적 조성물과 식품 조성물의 제제예Formulation Examples of Pharmaceutical Compositions and Food Compositions
<제제예 1> 캡슐제의 제조 Preparation Example 1 Preparation of Capsule
<참고예 6>의 대나무 추출물 5g, 옥수수 전분 100㎎, 유당 100㎎, 스테아린산 마그네슘2㎎를 완전히 혼합한 후 통상의 캡슐제의 제조 방법에 따라서 경질 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다. 5 g of the bamboo extract of <Reference Example 6>, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were completely mixed, and then filled into hard gelatin capsules according to a conventional method for preparing capsules.
<제제예 2> 주사제의 제조 Preparation Example 2 Preparation of Injection
<참고예 6>의 대나무 추출물 5g 적량의 주사용 증류수와 적량의 pH 조절제를 사용하여 통상의 주사제의 제조 방법에 따라 대나무 추출물을 주사용 증류수에 용해하고 pH를 약 7.5로 조절한 다음 전체를 주사용 증류수로 2㎖ 용량의 앰플에 충진하고 멸균시켜서 주사제를 제조하였다.5 g of the bamboo extract of <Reference Example 6> using a suitable amount of distilled water for injection and a pH adjusting agent, the bamboo extract was dissolved in distilled water for injection and adjusted to a pH of about 7.5 according to a conventional method for preparing an injection. Injections were prepared by filling a 2 ml ampoule with distilled water and sterilizing.
<제제예 3> 기능성 음료의 제조 Preparation Example 3 Preparation of Functional Drink
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 <참고예 6>의 대나무 추출물 5g을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.Instant sterilization by homogeneously combining 5 g of bamboo extract of <Reference Example 6> with subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%) After this, it was packaged in small packaging containers such as glass bottles and plastic bottles to prepare a healthy beverage.
전술한 바와 같이, 본 발명에 따르면 당뇨병 치료 또는 예방용 조성물과 당뇨병 합병증 치료 또는 예방용 조성물이 제공된다.As described above, the present invention provides a composition for treating or preventing diabetes and a composition for treating or preventing diabetes complications.
본 발명의 조성물들은 약제학적 조성물 또는 식품 조성물로 응용되어 사용될 수 있다.The compositions of the present invention can be applied and used as pharmaceutical compositions or food compositions.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050050175A KR100678568B1 (en) | 2005-06-13 | 2005-06-13 | Composition Comprising Bamboo Extract for Treating or Preventing Diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050050175A KR100678568B1 (en) | 2005-06-13 | 2005-06-13 | Composition Comprising Bamboo Extract for Treating or Preventing Diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060129610A KR20060129610A (en) | 2006-12-18 |
KR100678568B1 true KR100678568B1 (en) | 2007-02-02 |
Family
ID=37810400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050050175A KR100678568B1 (en) | 2005-06-13 | 2005-06-13 | Composition Comprising Bamboo Extract for Treating or Preventing Diabetes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100678568B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101688090B1 (en) | 2016-01-15 | 2016-12-21 | 강원대학교산학협력단 | Composition for anti-diabetes with the extract of Helianthus tuberosus, rice bran, Schizandra chinensis, Momordica charantin |
-
2005
- 2005-06-13 KR KR1020050050175A patent/KR100678568B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
동의생리병리학회지 17(1), 177-82 (2003) * |
중앙대학교 대학원 석사학위논문, '식물성 혈당강하제* |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101688090B1 (en) | 2016-01-15 | 2016-12-21 | 강원대학교산학협력단 | Composition for anti-diabetes with the extract of Helianthus tuberosus, rice bran, Schizandra chinensis, Momordica charantin |
Also Published As
Publication number | Publication date |
---|---|
KR20060129610A (en) | 2006-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101269208B1 (en) | Composition comprising sauchinone as an active ingredient for preventing or treating insulin resistance | |
KR101989739B1 (en) | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts | |
KR100678568B1 (en) | Composition Comprising Bamboo Extract for Treating or Preventing Diabetes | |
KR101680013B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient | |
KR101899555B1 (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
KR101187310B1 (en) | Composition comprising Citrus peel extract for the prevention and treatment of Type 2 Diabetes | |
KR100543405B1 (en) | Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus | |
KR100678562B1 (en) | Use of Bamboo Extract for Lowering Blood Pressure | |
US20100093852A1 (en) | Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizon for treating or preventing diabetes mellitus and the use thereof | |
KR100610565B1 (en) | Composition comprising mixture of the extract of grape seed and Salicornia herbacea for lowering blood glucose and treating and preventing obesity | |
KR20120089045A (en) | A composition comprising powder of amphicarpaea bracteata subsp.edgeworthii(benth.) h.ohashi and the extract thereof for preventing and treating diabetes mellitus and diabetic complication | |
KR101413771B1 (en) | A composition for anti-obesity comprising extract of big cone pine needle | |
KR101907179B1 (en) | Method for production of sulforaphene-enriched raphanus sativus seeds extracts and Food composition, pharmaceutical composition, animal medicines for weight and blood glucose control, fatty liver prevention with the raphanus sativus seeds extracts therefrom | |
KR100706134B1 (en) | Composition containing Cinnamomum camphora PRESL leaves extract or fractions thereof for prevention and treatment of diabetes | |
KR20160020638A (en) | Compostion for preventing or improving the metabolic syndrome containing Aeschynanthus acuminatus Wall. ex A. DC extract as agonist of GPR119 | |
KR20200031745A (en) | Pharmaceutical composition for prevention or treatment of non-alcoholic steatohepatitis containing tazemetostat or derivative thereof as an active ingredient | |
RU2805492C9 (en) | Method for correction of post-prandial glycemia | |
KR102292060B1 (en) | Composition comprising of the combined extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating obesity | |
KR20120139911A (en) | Composition comprising rice hulls extract for treating or preventing diabetes | |
RU2805492C1 (en) | Method for correction of post-prandial glycemia | |
KR101348471B1 (en) | A composition comprising Larrea cuneifolia Cav. for the prevention and treatment of menopausal symptom | |
KR20100108869A (en) | Composition containing extract of herbal mixture for prevention or treatment of diabetes | |
KR101662459B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient | |
KR100660961B1 (en) | Composition for Preventing or Treating Hepatoma | |
KR101219736B1 (en) | Composotion for facilitate secretion of testosterone comprising silk worm dry powder and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130102 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140110 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150105 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160105 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170109 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180125 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181120 Year of fee payment: 13 |